PTEN and cancer: Many cancer cells have enhanced mTORC1 activity resulting from upregulation of PI3K-Akt signaling, either due to enhanced mitogenic receptor activity, inactivating mutations in the negative regulator of PI3K signaling, phosphatase and tensin homolog (PTEN), or activating mutations in PI3K or Akt, or other mechanisms [122].